Clinical Trial ProgressSernova's Phase 1/2 study results are indicative of the trial being on track to succeed and help de-risk any upcoming data readouts and subsequent studies.
Product InnovationThe addition of tegoprubart to Sernova’s Cell Pouch platform is expected to enable patients to achieve insulin independence with significantly less toxicity.
Research CollaborationA new research agreement with Eledon Pharmaceuticals aims to enhance cell pouch safety in Sernova's clinical development, potentially improving the therapy for patients with type 1 diabetes.